Compare AbCellera Biologics Inc (ABCL) vs Shopify Inc. (SHOP) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Shopify (SHOP) trades at $121.88, up 2.03% on the day, with a bullish technical setup showing strong moving average signals and support near $117. Revenue grew to $11.56B in 2025 with a 10.77% net margin, though valuation multiples remain elevated. Recent news highlights Bank of America reinstating a Buy rating with a $150 target, citing AI commerce tools and partnership developments.

Outlook is positive with analyst consensus at $149.10 and 63% Buy ratings, but high P/E of 117.78 poses valuation risk. Key opportunities include AI-driven growth and expanding merchant services, while risks involve competitive pressures and reliance on e-commerce trends. Cash flow trends show improving operations, supporting continued investment in innovation.